No Data
Risks Still Elevated At These Prices As Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) Shares Dive 31%
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Cailong Pharmaceutical: 2024 Annual Results Forecast Revision Announcement
Sailong Pharmaceutical Group (002898.SZ): Voriconazole has received the approval notification for the listing application of Chemical Raw Materials.
Gelonghui, February 20, Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the approval notification for the listing application of Voriconazole as a Chemical Raw Material from the National Medical Products Administration. Voriconazole formulation is a broad-spectrum triazole antifungal agent primarily used to treat the following fungal infections: (1) Invasive aspergillosis. (2) Candidemia in patients with neutropenia. (3) Serious invasive infections caused by Candida species resistant to fluconazole (including Candida krusei). (4) Severe infections caused by the genera Scedosporium and Fusarium.
Cailong Pharmaceuticals: 2024 Annual Results Forecast
Some Confidence Is Lacking In Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) As Shares Slide 29%